Brofaromine (Consonar) is a reversible inhibitor of monoamine oxidase A discovered by Ciba-Geigy. The drug is primarily useful in the treatment of depression and anxiety. Brofaromine also has serotonin reuptake inhibitory properties and its dual pharmacologic effects offer promise in the treatment of a wide spectrum of depressed patients while producing less severe anticholinergic side effects in comparison with standard drugs although it is not commercially available and is not being actively researched, possibly due to a lack of financial interest.
Brofaromine is a reversible inhibitor of monoamine oxidase A (RIMA, a type of monoamine oxidase inhibitor (MAOI)) and acts on epinephrine (adrenaline), norepinephrine (noradrenaline), serotonin, and dopamine. Unlike standard MAOIs, possible side effects do not include cardiovascular complications (hypertension) with encephalopathy, liver toxicity or hyperthermia.